Wimalawansa SJ - Search Results

1

A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.

Wimalawansa SJ. Wimalawansa SJ. Am J Med. 1998 Mar;104(3):219-26. doi: 10.1016/s0002-9343(98)00029-1. Am J Med. 1998. PMID: 9552083 Clinical Trial.

2

Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study.

Wimalawansa SJ. Wimalawansa SJ. Am J Med. 1995 Jul;99(1):36-42. doi: 10.1016/s0002-9343(99)80102-8. Am J Med. 1995. PMID: 7598140 Clinical Trial.

3

Therapeutic success in severe iatrogenic osteoporosis in a young woman.

Wimalawansa SJ, Banks LM. Wimalawansa SJ, et al. J R Soc Med. 1993 Feb;86(2):117-8. J R Soc Med. 1993. PMID: 8433299 Free PMC article. No abstract available.

4

Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.

Wimalawansa SJ, Gunasekera RD. Wimalawansa SJ, et al. Calcif Tissue Int. 1993 Oct;53(4):237-41. doi: 10.1007/BF01320908. Calcif Tissue Int. 1993. PMID: 8275351 Clinical Trial.

5

Long- and short-term side effects and safety of calcitonin in man: a prospective study.

Wimalawansa SJ. Wimalawansa SJ. Calcif Tissue Int. 1993 Feb;52(2):90-3. doi: 10.1007/BF00308314. Calcif Tissue Int. 1993. PMID: 8443697 Clinical Trial.

6

Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.

Wimalawansa SJ. Wimalawansa SJ. Clin Endocrinol (Oxf). 1994 Nov;41(5):591-5. doi: 10.1111/j.1365-2265.1994.tb01823.x. Clin Endocrinol (Oxf). 1994. PMID: 7828347 Clinical Trial.

7

Prevention and treatment of osteoporosis: efficacy of combination of hormone replacement therapy with other antiresorptive agents.

Wimalawansa SJ. Wimalawansa SJ. J Clin Densitom. 2000 Summer;3(2):187-201. doi: 10.1385/jcd:3:2:187. J Clin Densitom. 2000. PMID: 10871912 Review.

8

Antihypertensive effects of oral calcium supplementation may be mediated through the potent vasodilator CGRP.

Wimalawansa SJ. Wimalawansa SJ. Am J Hypertens. 1993 Dec;6(12):996-1002. doi: 10.1093/ajh/6.12.996. Am J Hypertens. 1993. PMID: 8136100 Clinical Trial.

9

Calcitonin for prevention of postmenopausal bone loss.

MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, Healy MJ. MacIntyre I, et al. Among authors: wimalawansa sj. Lancet. 1988 Apr 23;1(8591):900-2. doi: 10.1016/s0140-6736(88)91712-6. Lancet. 1988. PMID: 2895829 Clinical Trial.

10

Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.

Wimalawansa SJ. Wimalawansa SJ. Cancer. 1994 Apr 15;73(8):2223-30. doi: 10.1002/1097-0142(19940415)73:8<2223::aid-cncr2820730831>3.0.co;2-c. Cancer. 1994. PMID: 8156530 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

167 results

Search Page